Akeso Biomedical Receives EU Authorization for CI-FER® as a Feed Additive in Piglets
Retrieved on:
Monday, November 1, 2021
Salmonella, Food safety, Efficiency, Technology, University, III, Zinc oxide, Foodborne illness, European Union, Cementite, Disease, EFSA, Iron, Campylobacter, Oxidative stress, European Food Safety Authority, Professor, CEO, Diarrhea, Escherichia coli, Union, Solution, Health, Mortality, Gene expression, Colon, Medical device, Pig
BURLINGTON, Mass., Nov. 1, 2021 /PRNewswire/ -- Akeso Biomedical, Inc., announced today that the company has obtained authorization in the European Union to market CI-FER® as a zootechnical feed additive for piglets and minor porcine species. Akeso Biomedical is a privately held company developing novel, non-antibiotic feed additive technologies to improve gut health and animal performance.
Key Points:
- BURLINGTON, Mass., Nov. 1, 2021 /PRNewswire/ --Akeso Biomedical, Inc., announced today that the company has obtained authorization in the European Union to market CI-FER as a zootechnical feed additive for piglets and minor porcine species.
- Akeso Biomedical is a privately held company developing novel, non-antibiotic feed additive technologies to improve gut health and animal performance.
- CI-FER [iron (III) citrate chelate] for piglets is Akeso's first product for the EU market based on its Fe3C technology.
- The company conducted five efficacy studies in the EU to demonstrate that piglets receiving CI-FER grew faster, exhibiting higher body weights and better feed efficiency than control piglets.